Revvity
A global life sciences and diagnostics company serving pharmaceutical, biotechnology, research, and clinical laboratories.
Last updated November 3, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Revvity, Inc. is a United States-based life sciences and diagnostics company headquartered in Waltham, Massachusetts. The company emerged from the 2022 separation of PerkinElmer and began operating under the Revvity name in 2023. Its business is centered on technologies, reagents, software, and services used in biological research, drug discovery, genetic analysis, clinical diagnostics, and newborn screening. The company’s origins are tied to PerkinElmer, a long-established scientific and healthcare business that had accumulated activities across life sciences, diagnostics, food testing, environmental and applied services, and other laboratory markets. In the separation, the life sciences and diagnostics activities remained a publicly traded company, while PerkinElmer’s applied, food, and enterprise-services activities were sold to New Mountain Capital and continued under the PerkinElmer name. The public company adopted the name Revvity in 2023, combining ideas associated with revolution and life. Its shares began trading under the RVTY ticker on May 16, 2023, replacing PerkinElmer’s former PKI symbol. Revvity focuses particularly on areas where pharmaceutical and biotechnology research is moving toward cell therapy, gene therapy, precision medicine, high-throughput biology, and genomic testing. Its portfolio includes high-content imaging and screening systems, single-cell and spatial biology tools, genetic analysis platforms, base-editing technologies, laboratory automation, immunodiagnostic assays, newborn-screening products, and scientific software. Its BioLegend business contributes antibodies, flow-cytometry reagents, and other research products, while Euroimmun and Immunodiagnostic Systems support infectious-disease, autoimmune, endocrine, allergy, and other clinical testing applications. Compared with the broader PerkinElmer structure, Revvity has emphasized consumables, reagents, software, digital workflows, and recurring customer relationships alongside instruments. This approach is intended to support higher-margin and more growth-oriented activities while retaining a broad installed base of laboratory technologies. The company sells to pharmaceutical and biotechnology companies, academic and government research institutions, hospitals, diagnostic laboratories, public-health programs, and contract research organizations. Its diagnostics activities include automated immunoassay systems, molecular newborn screening, tests for genetic and infectious diseases, and laboratory automation. In research, the company supplies tools for cellular analysis, protein profiling, genomics, drug screening, and genome editing. Revvity also participates in collaborations involving newborn genomic screening, AI-enabled drug discovery, cell therapy research, and diagnostic reference standards. Revvity remains an independent, publicly listed company. Its present identity reflects a deliberate separation from the diversified PerkinElmer portfolio and a strategic concentration on life sciences and diagnostics. The company’s current direction combines laboratory hardware with recurring reagents, software, services, and partnerships intended to support increasingly automated and data-intensive research and clinical workflows.
History
Revvity’s history is inseparable from the development of PerkinElmer, a diversified scientific and healthcare company whose activities extended across laboratory instruments, life sciences, diagnostics, food testing, environmental services, and applied testing. Over time, PerkinElmer assembled businesses serving both research laboratories and clinical markets. Its life sciences and diagnostics operations developed capabilities in imaging, cellular analysis, genomics, immunodiagnostics, newborn screening, laboratory automation, and scientific software. A major corporate restructuring took place in 2022. PerkinElmer separated its business into two substantially different groups. The applied, food, and enterprise-services activities were sold to New Mountain Capital for $2.45 billion and continued as a private company using the PerkinElmer name. The life sciences and diagnostics activities remained publicly traded. This surviving public business was the larger part of the former organization, with approximately 11,000 employees assigned to it at the time of the separation, compared with roughly 6,000 employees moving to the private PerkinElmer business. Because the PerkinElmer name remained associated with the divested private company, the public life sciences and diagnostics business required a new identity. In 2023 it announced the name Revvity. The name was constructed from concepts related to revolution and vita, the Latin word for life, reflecting the company’s intended focus on technological change in biology and healthcare. Its headquarters remained in Waltham, Massachusetts, where the former PerkinElmer organization had been based. The transition was completed in the public markets on May 16, 2023, when the company’s shares began trading under RVTY instead of PerkinElmer’s PKI symbol. Several senior leaders continued from PerkinElmer, while the new organization also recruited or appointed additional executives. The separation was presented as a way to give the life sciences and diagnostics activities a clearer strategic focus, greater financial flexibility, and the opportunity to pursue growth and profitability profiles different from those of the divested services businesses. Revvity’s operating model places increasing emphasis on reagents, consumables, software, automation, and digitally enabled workflows rather than relying primarily on capital instruments. Its research portfolio supports drug discovery, high-content screening, cellular analysis, single-cell biology, protein profiling, genomics, and gene-editing research. Its diagnostics portfolio includes immunoassays, infectious-disease and autoimmune testing, endocrine testing, molecular newborn screening, and automated laboratory systems. After the rebrand, Revvity continued expanding through product certifications, research collaborations, and clinical-development partnerships. Euroimmun’s UNIQO 160 obtained CE-IVDR certification in 2023, while the EONIS Q system received CE-IVD certification for molecular screening of spinal muscular atrophy and severe combined immunodeficiency. The company subsequently pursued FDA clearances and European regulatory markings for additional endocrine, infectious-disease, tuberculosis, and immunodiagnostic products. Revvity has also developed partnerships around genome sequencing, newborn screening, cell therapy, base editing, AI-enabled drug discovery, and diagnostic quality standards. These activities position the company between research technology and clinical diagnostics, with a strategy based on connecting laboratory hardware, biological reagents, software, and services into repeatable workflows. It remains an active publicly listed company focused on life sciences and diagnostics.
- 2025
Euroimmun receives FDA clearance for free testosterone testing
[2]The FDA clears a chemiluminescence immunoassay for quantitative free-testosterone measurement.
- 2025
Revvity receives FDA approval for Auto-Pure 2400 with T-SPOT.TB
[2]The combined automation and assay workflow is approved for automated latent-tuberculosis detection.
- 2023
Revvity name announced
[1]The retained life sciences and diagnostics business adopts Revvity as its new corporate identity.
- 2023
Shares begin trading as RVTY
[1]The public company’s former PKI ticker is replaced by RVTY on May 16.
- 2023
UNIQO 160 receives CE-IVDR certification
[2]Euroimmun’s automated indirect immunofluorescence testing system receives European regulatory certification.
- 2023
EONIS Q receives CE-IVD certification
[2]The molecular newborn-screening system is certified for SMA and SCID testing applications.
- 2022
PerkinElmer separates its business activities
[1]PerkinElmer sells its applied, food, and enterprise-services businesses to New Mountain Capital while retaining the life sciences and diagnostics activities as a public company.
Products and positioning
A specialized life sciences and diagnostics technology company combining instruments, reagents, automation, software, and clinical testing workflows for research and healthcare applications.
Cell biology and imaging
High-content screening systems
Revvity’s high-content screening portfolio combines automated microscopy, image acquisition, and computational analysis to measure cellular phenotypes at scale. These systems are used in drug discovery, toxicology, disease modeling, and cell-biology research, helping laboratories evaluate large numbers of compounds or biological conditions while capturing multiparametric information from individual cells.
Research reagents
BioLegend reagents
BioLegend supplies antibodies, flow-cytometry reagents, proteins, kits, and related products for immunology, cell biology, oncology, and other research fields. The portfolio supports phenotyping, protein detection, cellular characterization, and single-cell workflows used by academic, pharmaceutical, and biotechnology laboratories.
Molecular diagnostics · 2023
EONIS Q
EONIS Q is a molecular testing system used in newborn-screening applications. Its certified applications include screening related to spinal muscular atrophy and severe combined immunodeficiency, conditions in which early identification can support timely clinical evaluation and treatment decisions.
Immunodiagnostics · 2023
UNIQO 160
UNIQO 160 is an automated indirect immunofluorescence testing platform from Euroimmun. It integrates sample preparation, incubation, slide washing and mounting, image acquisition, and image analysis, helping laboratories standardize a workflow used for autoimmune and other antibody-based investigations.
Gene-editing research
Pin-point base editing
Pin-point is Revvity’s base-editing technology platform for research applications. It is designed to support targeted genetic modification without relying solely on conventional double-strand DNA breaks and has been made available to collaborators working on cell therapy, oncology, immune-mediated disease, and enzyme engineering research.
Scientific software
Signals software
Signals is Revvity’s software environment for scientific data, laboratory workflows, research informatics, and decision support. It is intended to connect experimental information and analytical tools across discovery organizations, supporting more structured and collaborative research processes.
Marketing campaigns
- 2025Generation Study collaboration
United Kingdom
Revvity expanded its work with Genomics England on initiatives including the Generation Study, which evaluates whole-genome sequencing for screening up to 100,000 newborns for rare genetic disorders.
Outcome. Expanded participation in population-scale genomic screening research.
- 2024Early Check genomic screening collaboration
United States · North Carolina
Revvity worked with RTI International to provide genome sequencing for Early Check, a voluntary newborn-screening research study designed to examine testing for childhood-onset genetic conditions beyond conventional screening panels.
Outcome. Supported ongoing evaluation of expanded genomic newborn screening.
Brand decisions
2023
Adopt the Revvity identity and focus on life sciences and diagnosticsStrategyBackground
The public company needed a distinct identity after the PerkinElmer name remained with the divested private business.
Action taken
The company adopted Revvity as its corporate name and concentrated its positioning on life sciences, diagnostics, reagents, software, and related services.
Aftermath
The company began trading under RVTY and presented itself as a more focused life sciences and diagnostics business.
2023
License Pin-point base-editing technology to AstraZenecaOtherBackground
AstraZeneca sought access to base-editing capabilities for research in cancer and immune-mediated diseases.
Action taken
Revvity entered a non-exclusive licensing agreement providing AstraZeneca access to Pin-point technology.
Aftermath
The agreement extended use of Revvity’s gene-editing platform in pharmaceutical research.
2022
Separate the applied-services businesses from life sciences and diagnosticsM&ABackground
PerkinElmer pursued a corporate separation to distinguish its life sciences and diagnostics operations from applied, food, and enterprise-services activities.
Action taken
The applied, food, and enterprise-services businesses were sold to New Mountain Capital, while the life sciences and diagnostics businesses remained publicly traded.
Aftermath
The retained public business was renamed Revvity in 2023 and continued under the RVTY ticker.
Transaction value. $2.45 billion sale of the divested businesses (2022)
Recent events
Revvity raises full-year EPS guidance[4]
Reported:
Revvity raised its full-year pro forma adjusted earnings-per-share guidance to $5.40–$5.45 from $5.30–$5.40.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/revvity · Editorial policy · How profiles are compiled